Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Maxwell

Thoracic Surgery (Cardiothoracic Vascular Surgery) Bozeman, MT Medical Doctor

NPI 1114926300 CMS profile 594161

915 Highland Blvd, Bozeman, MT 59715

Open in the dashboard

General payments

$5,852

116 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Maxwell of Bozeman, MT is reported in the CMS Open Payments database as having received $5,852 across 116 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,293 21
2024 General $1,411 25
2023 General $609 9
2022 General $1,148 23
2021 General $572 13
2020 General $583 17
2019 General $236 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Maxwell
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to Michael Maxwell were reported at $1,293. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year Michael Maxwell Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $236 $886 $178–$3,167 $163
2020 $583 $341 $108–$1,605 $114
2021 $572 $453 $125–$1,886 $132
2022 $1,148 $695 $180–$2,566 $149
2023 $609 $745 $205–$2,662 $160
2024 $1,411 $799 $214–$2,967 $164
2025 $1,293 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $1,679 24 payments
  2. Abbott Laboratories $1,303 23 payments
  3. Abiomed $836 10 payments
  4. Medtronic, Inc. $625 14 payments
  5. Edwards Lifesciences Corporation $296 2 payments
  6. Cook Medical LLC $199 6 payments
  7. HeartFlow, Inc. $113 1 payment
  8. Bolton Medical Inc $95 3 payments
  9. Ethicon US, LLC $95 4 payments
  10. Atricure, Inc. $82 3 payments
  11. Other $529 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,837 115 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. EPIC $756 13 payments
  2. Impella $755 7 payments
  3. EXCLUDER Conformable AAA Endoprosthesis with Active Control $690 9 payments
  4. Epic Stented Tissue Valve $411 6 payments
  5. GORE TAG Conformable Thoracic Endoprosthesis $342 4 payments
  6. Avalus $223 3 payments
  7. GORE VIABAHN VBX Balloon Expandable Endo $205 2 payments
  8. C3 Delivery System $189 2 payments
  9. COREVALVE EVOLUT R $173 2 payments
  10. EXCLUDER AAA Endoprosthesis $166 3 payments
  11. Other $2,081 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

40

Median for Cardiac Surgery: 68

Drug cost

$7,886

Median for Cardiac Surgery: $445

Branded share of claims

65%

Median for Cardiac Surgery: 15.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 14 $7,720
Oxycodone Hcl Generic 14 $89
Clopidogrel Clopidogrel Bisulfate Brand 12 $78

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 411 Part D prescribers listed as Cardiac Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 100 billing codes

Paid by Medicare

$159,808

Medicare's payments for the services billed

Medicare patients

275

Average age 75

Services billed

615

89 women, 186 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 69%
Atrial fibrillation 49%
Arthritis 49%
Chronic kidney disease 47%
Diabetes 43%
Heart failure 41%
COPD 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

116 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record